ArticlePloS one2026
Safety population size and duration of exposure prior to approval of new medicines: A database analysis of medicines centralised approved in the European Union between 2011 and 2023.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to analyse the number of patients who had been exposed to a new medicine before the approval by the European Commission (EC), as well as the number of patients studied long-term for chronic medication use. The results were compared with the International Council for Harmonisation's (ICH) E1 guideline recommendations.
methodsAll medicines containing new active substances approved between 2011 and 2023 were included in the study, including orphan medicines as a separate category. The total number of patients studied and the number of patients with long-term use (6 and 12 months) for chronic medication before approval were extracted. In addition, information regarding the type of Marketing Authorisation (MA), type of molecule, Anatomical Therapeutic Chemical (ATC) code and additional pharmacovigilance activities were extracted from the European Public Assessment Report (EPAR).
resultsA total of 498 new medicines were identified, of those 322 were non-orphan medicines and 176 were orphan medicines. The median total number of patients studied before approval was 1,787 (interquartile range [IQR] 781-3,351) for non-orphan medicines and 333 (IQR 139-648) for orphan medicines. In the group of non-orphans, chronic medication was studied in a larger number of patients (median 2,253, IQR 1,523-3,662) than medication for intermediate (median 798, IQR 520-1,757) or short-term use (median 2,038, IQR 807-6,110). Among the 154 non-orphan medicines intended for chronic use, 83 (54%) met the patient exposure recommendations for 6-months use, and 113 (73%) met the criteria for 12-months patient exposure. Among the 101 orphan medicines intended for chronic use, only 1 (1%) met the patient exposure recommendations for 6-months use and 7 (6.9%) met the criteria for 12-months patient exposure.
conclusionOrphan medicines and "precision" medicines tend to have less clinical data available at the time of marketing authorisation. The median of the total number of subjects studied prior to approval has been decreasing overtime. Additional pharmacovigilance activities play, in these cases, a key role in the safety monitoring and assessment of the benefit-risk profile during the medicine's lifecycle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.